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Heterozygous SSBP1 start loss mutation
co-segregates with hearing loss and the
m.1555A4G mtDNA variant in a large
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The m.1555A4G mtDNA variant causes maternally inherited deafness, but the reasons for the highly variable clinical penetrance
are not known. Exome sequencing identiﬁed a heterozygous start loss mutation in SSBP1, encoding the single stranded binding
protein 1 (SSBP1), segregating with hearing loss in a multi-generational family transmitting m.1555A4G, associated with mtDNA
depletion and multiple deletions in skeletal muscle. The SSBP1 mutation reduced steady state SSBP1 levels leading to a perturb-
ation of mtDNA metabolism, likely compounding the intra-mitochondrial translation defect due to m.1555A4G in a tissue-speciﬁc
manner. This family demonstrates the importance of rare trans-acting genetic nuclear modiﬁers in the clinical expression of
mtDNA disease.
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Introduction
Mitochondrial dysfunction causes hearing loss in isolation
and as a feature of multi-systemic mitochondrial disease.
The mitochondrial variant m.1555A4G in the 12S
ribosomal RNA gene MTRNR1, is present at an estimated
1 in 385 (0.26%) of the European population, and is
necessary but not sufﬁcient to cause maternally inherited
deafness (Prezant et al., 1993; Rahman et al., 2012).
Aminoglycosides are a recognized modiﬁer factor but
cannot account for all hearing-impaired carriers in multi-
generational pedigrees, implicating additional co-segregat-
ing genetic factors (Bykhovskaya et al., 1998; Guan
et al., 2006).
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Here, we report a multi-generational family where a het-
erozygous start loss mutation in the core mitochondrial
DNA (mtDNA) replisome protein gene, single stranded
binding protein 1 (SSBP1), co-segregated with the
m.1555A4G variant and the phenotype. This provides




Forty-six individuals (21 female: 25 male) carrying the
m.1555A4G mtDNA variant from Northern Finland (Fig.
1A) were previously described (Hakli et al., 2013).
Individuals in Generation IV (nine females: 10 males) either
have normal hearing (n = 9) or sensorineural hearing loss
[n = 10, moderate high frequency (2–8 kHz) hearing loss n = 3,
moderate pan-frequency (0.25–8 kHz) hearing loss n = 6, pro-
found pan-frequency hearing loss n = 1]. The mean age of
hearing loss diagnosis was 3.7 years (range 1.6–5.4 years).
There was no history of aminoglycoside usage. Neurological
examination of all individuals was otherwise normal. There
was no clinical evidence of either proximal or distal myopathy.
DNA was available from 25 individuals from Generation III
and IV. We subsequently also identiﬁed the children of two
fathers in Generation III [Subject III-6 (P1), father in Family D,
n = 9 children; and Subject III-10 (P4), father in Family E,
n = 6 children; mean age of children = 10.3 years (range 1–
19 years); Fig. 1A(i)]. Fibroblast cell lines were established
from Subjects III-6 (P1) and III-5 (P2). We also studied ﬁbro-
blasts and DNA from an unrelated individual carrying
m.1555A4G (Subject P3). Skeletal muscle biopsy was ob-
tained from Subjects III-10 (P4, age 38 years) and III-8 (P5,
age 41 years).
Molecular genetics
Exome sequencing, variant calling and ﬁltering to isolate het-
erozygous candidate variants with a minor allele frequency
(MAF) 51% were performed as previously described (Keogh
et al., 2015). Sanger sequencing was performed to conﬁrm
segregation of the SSBP1 variant. Pyrosequencing (Qiagen)
was undertaken for allelic quantiﬁcation of m.1555A4G.
Long-range PCR was used to detect mtDNA deletions using
primers (D1R m.19-1 and D2F m.1650-1671) amplifying a
product encompassing almost the complete mtDNA. mtDNA
copy number was determined using real time PCR TaqMan
assays targeting MT-ND1 or MT-CO3 and the nuclear genes,
B2M or RNaseP as described (Grady et al., 2014). Total DNA
was prepared by phenol-chloroform extraction and precipita-
tion for 7S DNA analysis, then linearized by PvuII digestion
before electrophoresis on 0.7% agarose gels and Southern hy-
bridization (Kornblum et al., 2013). RNA was extracted from
ﬁbroblast cell lines using RNeasy Mini Kit (Qiagen) and
cDNA was synthesized using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Quantiﬁcation of
gene expression was performed using the TaqMan Gene
Expression Assay using transcript speciﬁc primers for SSBP1
and MT-CYB with normalization to GAPDH.
Biochemical analysis of the oxidative
phosphorylation system
Protein extract from ﬁbroblasts was separated by electrophor-
esis on a 4–12% polyacrylamide gel (NuPAGE). Immunoblot-
ting was performed as described using antibodies to SSBP1,
(12212-1-AP, Proteintech), mitochondrially encoded cyto-
chrome c oxidase 1 (MT-CO1, ab14705, Abcam), mitochond-
rially encoded cytochrome c oxidase 2 (MT-CO2, 12C4F12,
Abcam), succinate dehydrogenase complex ﬂavoprotein subunit
A (SDHA, ab14715, Abcam), ATP synthase subunit alpha
(ATP5A, MS604, Mitosciences), translocase of outer membrane
20 (TOMM20, ab56783, Abcam) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH, sc-25778, Santa-Cruz) (Pfeffer
et al., 2014). Cellular oxygen consumption rate (OCR) was
assayed using the Seahorse XF96 Extracellular Flux Analyser
with sequential addition of oligomycin (1 mM), carbonyl cyan-
ide 4-(triﬂuoromethoxy)phenylhydrazone (FCCP, 1mM) and
rotenone/antimycin (1mM) to measure basal and maximal res-
piration. Cell growth was assessed by growing ﬁbroblast cells
with high glucose medium versus glucose-free medium supple-
mented with 5mM galactose using IncuCyte Live Cell imager,
Essen Bioscience.
Muscle histochemistry
Haematoxylin and eosin, cytochrome c oxidase (COX), suc-
cinate dehydrogenase (SDH) and sequential COX-SDH stain-
ing was performed on sectioned skeletal muscle (10 mm
transverse sections) as previously described (Taylor et al.,
2004).
Intra-mitochondrial translation assay
Metabolic labelling of mitochondrial proteins was performed
as previously described (Van Haute et al., 2016). Loading was
assessed by western blotting for TOMM20.
Results
Sequencing analysis
Pyrosequencing of leucocyte DNA conﬁrmed all subjects
were homoplasmic for m.1555A4G (Fig. 1C). Exome
sequencing was performed on four affected individuals
[Subjects III-6 (P1), III-10 (P4), IV-4 (Family A) and IV-2
(Family B)]. Average coverage 510 fold was obtained for
93.2% of bases (range 89.6–94.9%). After ﬁltering, we
identiﬁed a heterozygous c.3G4A variant in SSBP1
(NM_001256510:exon2:c.G3A:p.M1?) that abolishes the
primary start codon (Fig. 1B). The variant is found in 16
of 267 458 sequenced alleles in the gnomAD database
(http://gnomad.broadinstitute.org). All of the variants
were found in Finnish individuals (16 of 25 294 sequenced
alleles), possibly indicating a founder effect within the
Finnish population. The variant is predicted to be patho-
genic by MutationTaster = 1, SIFT = 0 and LRT = 0 (Chun
and Fay, 2009; Kumar et al., 2009; Schwarz et al., 2010).
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Figure 1 Clinical features and genetic effect of the m.1555A`G and SSBP1 variants. (A) Family segregating m.1555A4G mtDNA
variant and the c.3G4A SSBP1 nuclear gene variant. Individuals in Generation III, 1–12 marked in black; individuals in Generation IV: Family A 1–6,
Family B 1–9, Family C 1–4; marked in green. Allelic status for the c.3G4A SSBP1 is given below each tested individual. Symbols are as follows:
filled = hearing loss; unfilled = normal hearing; asterisk = exome sequenced individual; red box III-6 = Subject P1; blue box III-5 = Subject P2; green
box III-10 = Subject P4; orange box III-8 = Subject P5. [A(i)] Families of III-6, P1 (n = 9 children, Family D) and III-10, P4 (n = 6 children, Family E).
Allelic status for the c.3G4A SSBP1 is given below each tested individual. (B) Schematic overview of genomic structure of SSBP1. Heterozygous
start loss mutation, c.3G4A, abolishes primary translation start codon resulting in an effective null allele. (C) Representative pyrosequencing
trace revealing the homoplasmic m.1555A4G mtDNA variant in Subjects P1, P2, P3. Quantified allele (G/A at m.1555) marked by blue shading.
(D) Sequencing electropherogram from Subjects P1, P2, and P3 (unrelated m.1555A4G carrier). Subjects P1 and P2 are heterozygous for SSBP1
c.3G4A, P3 is wild-type. (E) Western blot analysis reveals markedly decreased levels of SSBP1 steady state levels in Subjects P1 and P2 compared
to Subject P3 and controls. Representative of three independent experiments. (F) SSBP1 mRNA analysed by quantitative PCR reveals no
difference between Subjects P1 and P2 compared to Subject P3 and controls (n = 3). Data represent mean  SD of three biological replicates.
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Figure 2 Muscle histochemistry and mtDNA copy number, analysis of cellular respiration and cell growth. (A) Muscle histo-
chemistry of Patient P5. Sequential cytochrome c oxidase / succinate dehydrogenase (COX/SDH) staining reveals the presence of COX negative
fibres (yellow arrow) and COX intermediate fibres (blue arrow). Haematoxylin and eosin (H&E) staining reveals fibre size variation within normal
limits. (B) Long range PCR of muscle DNA shows evidence of multiple mtDNA deletions. Lane 1 = DNA size marker; Lane 2 = Subject P4; Lane
3 = Subject P5; Lane 4 = Control. (C) mtDNA copy number analysis as determined by qPCR targeting MT-CO3 and RNaseP, Subject P4 = 35.8  4,
Subject P5 = 36.5  13.3% of controls (n = 2). Data represent mean  SD of two independent determinations, *P5 0.05, one-way ANOVA
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Sanger sequencing demonstrated the variant segregated
with the hearing loss in all sequenced individuals in
Generation III and IV (Fig. 1A and D). Sanger sequencing
revealed children in Family D (n = 8/9, 89%) and Family E
(n = 2/6, 33%) carried the c.3G4A SSBP1 but all carried
wild-type m.1555A [Fig. 1A(i)]. Subject P3 and a cohort of
nine unrelated hearing-impaired m.1555A4G carriers had
a wild-type SSBP1 sequence.
SSBP1 protein levels
Western blotting revealed decreased steady-state SSBP1
levels in ﬁbroblasts from Subjects P1 and P2 compared to
the m.1555A4G cell line (Subject P3) and controls
(Subjects C1–3) (Fig. 1E). No signiﬁcant difference in the
mRNA expression of SSBP1 was found between patient
and control ﬁbroblasts (Fig. 1F), consistent with the variant
abolishing SSBP1 translation without an effect on
transcription.
Muscle and fibroblast mtDNA
analysis
Haematoxylin and eosin staining of the muscle biopsy from
Subject P5 was unremarkable whereas sequential COX-
SDH staining revealed evidence of respiratory chain
deﬁciency with a low number of COX-deﬁcient and
COX-intermediate ﬁbres (5/174, 3.4%, Fig. 2A) (Murphy
et al., 2012). Long-range PCR of muscle DNA from
Subjects P4 and P5 showed the presence of multiple
mtDNA deletions (Fig. 2B), and muscle mtDNA copy
number was reduced by 60% in Subjects P4 and P5 com-
pared to controls (Fig. 2C), both suggestive of disordered
mtDNA maintenance. We did not detect mtDNA copy
number changes in patient blood or ﬁbroblast DNA
[Fig. 3A(i)], thus demonstrating tissue speciﬁcity.
Respiration and growth analysis
Measurement of cellular OCR in patient and control ﬁbro-
blasts revealed no signiﬁcant difference in basal OCR but a
trend of lower maximal respiration in Subjects P1, P2 and
P3 compared to controls (Fig. 2D). Subject P1, P2 and P3
cells had signiﬁcantly greater doubling times than controls
when galactose was used as a carbon source (Fig. 2E
and F).
7S DNA analysis
Mammalian mtDNA molecules contain a triple-stranded
region (D-loop) found in the major non-coding of many
mitochondrial genomes, formed by stable incorporation of
a third, short DNA strand known as 7S DNA. The exact
function of 7S DNA is unknown; however, it has been
proposed to play a role in replication as an intermediate
of prematurely-terminated heavy (H-) strand synthesis and
moreover, perturbations in the steady-state levels of 7S
DNA have been observed in a mtDNA maintenance dis-
order (Kornblum et al., 2013; Nicholls and Minczuk,
2014). Previous work has shown that SSBP1 is required
for mtDNA replication and regulates the mtDNA D-loop
by modulating the synthesis of 7S DNA (Ruhanen et al.,
2010). We analysed the abundance of 7S DNA relative to
genome length mtDNA molecules in patient and control
ﬁbroblasts. Subjects P1 and P2 had signiﬁcantly reduced
7S DNA abundance compared to Subject P3 and controls.
There was no difference in the level of full-length mtDNA
relative to nuclear 28S DNA in Southern blots, conﬁrming
the lack of difference in mtDNA copy number in Subject
P1, P2 and P3 ﬁbroblasts compared to controls [Fig. 3A
and A(i)].
Mitochondrial mtDNA transcription
and protein synthesis in fibroblasts
Measurement of de novo intra-mitochondrial protein trans-
lation by incorporation of 35S radiolabelled methionine re-
vealed markedly reduced global mitochondrial protein
synthesis in Subject P1, P2 and P3 cells compared to con-
trols [Fig. 3B and B(i)]. Reduction in protein synthesis in
patient cells was accompanied by a reduction in the steady
state levels of mtDNA-encoded complex IV subunits, MT-
CO1 in Subjects P1 and P2 and MT-CO2 in Subjects P1,
P2 and P3 [Fig. 3D and D(i)]. There was no difference in
steady state levels of nuclear encoded mitochondrial pro-
teins ATP5A and SDHA (Fig. 3D) or in MT-CYB mRNA
expression (Fig. 3C). Together these ﬁndings reveal a defect
in mitochondrial translation mediated by m.1555A4G that
was no more severe in the presence of the SSBP1 variant.
Discussion
Here we describe a heterozygous start loss mutation in
SSBP1 co-segregating with hearing loss in a maternal
Figure 2 Continued
with post hoc Tukey test. (D) Measurement of cellular oxygen consumption rate by Seahorse XF96 Extracellular Flux Analyser reveals a trend
towards lower maximal respiration in Subjects P1, P2, P3 compared to controls (n = 3). Data represent mean  SD of four independent
experiments. (E) Cellular growth curve analysis of Subejects P1, P2, P3 and control on glucose (green line) and glucose-free media supplemented
with 5 mM galactose (red line). Graphs represent cell confluency (%) versus time elapsed (h). Data representative of three independent experiments.
(F) Quantification of doubling time (DT) of Subjects P1, P2, P3 and controls (n = 2) in galactose media normalized to growth on glucose media. Data
represent mean doubling time  SD of three independent experiments, **P4 0.01, one-way ANOVA with post hoc Tukey test.
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Figure 3 7S DNA, mtDNA copy number, intra-mitochondrial translation and mitochondrial gene expression. (A) Southern blot
analysis of mtDNA copy number and 7S DNA levels in Subjects P1, P2, P3 and control fibroblasts. PvuII digested DNA was hybridized with a
radiolabelled probe A (mtDNA position 16270–16292 and 389–369), which detects both genomic mtDNA and 7S. 28S was used as a loading
control. [A(i)] Quantification of mtDNA and 7S DNA levels in Subjects P1, P2, P3 and control. 7S DNA levels normalized to genomic mtDNA
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pedigree transmitting the m.1555A4G variant. The back-
ground frequency of m.1555A4G in northern Finland has
been estimated to be signiﬁcantly less than in other
European populations (0.0047% versus 0.26%, Fisher’s
exact P4 0.001) reducing the likelihood that our observa-
tions are the result of a chance ﬁnding (Lehtonen et al.,
2000; Rahman et al., 2012).
The SSBP1 mutation reduced SSBP1 levels, decreased 7S
DNA in ﬁbroblasts, and was associated with multiple
deletions of mtDNA and mtDNA depletion in skeletal
muscle. Fibroblasts from these patients also showed
reduced intra-mitochondrial protein synthesis in keeping
with the co-existing m.1555A4G variant, leading to
reduced proliferation rates under conditions of forced mito-
chondrial respiration (Guan et al., 1996).
Patients with defects in POLG, another mitochondrial
maintenance gene encoding the mitochondrial DNA poly-
merase, pol, are thought to accumulate mtDNA deletions
by replication stalling at homopolymeric tracts. It has been
proposed that SSBP1 reduces arrests within these tracts,
and thus suppresses mtDNA deletion formation
(Mikhailov and Bogenhagen, 1996). Given that SSBP1
also coats the H-strand during replication, low SSBP1
levels in our patients may increase mtDNA replication
stalling and non-speciﬁc replication initiation, compromis-
ing replication ﬁdelity leading to tissue-speciﬁc mtDNA de-
letion and depletion (Miralles Fuste et al., 2014). The
observed reduction in 7S DNA in Subjects P1 and P2 ﬁbro-
blasts is in keeping with dysfunctional mtDNA replication.
The absence of detectable mtDNA deletions in ﬁbroblasts is
well recognized in mtDNA maintenance disorders (Stewart
et al., 2011), probably because the deletions are rapidly lost
in rapidly dividing cells.
Of note, we speciﬁcally searched for a common variant in
TRMU (c.28G4T p.A10S, gnomAD frequency = 0.097),
that has previously been suggested to modify the phenotype
in a subset of m.1555A4G carriers (Guan et al., 2006;
Meng et al., 2017). Reﬂecting this allele frequency, the
variant was found in both hearing impaired (3/8, 37.5%)
and normal hearing (2/5, 40%) individuals in the family, so
cannot account for the phenotype in our patients. Similarly,
the SSBP1 variant is unlikely to be pathogenic in isolation
given that 10/15 (67%), of the children in Families D and E
carry the SSBP1 variant in conjunction with wild-type
m.1555A and all have normal hearing. In addition, the
heterozygous knockout mouse Ssbp1tm1a(KOMP)Wtsi displays
only a mild phenotype, with hearing no different to wild-
type littermates (Brown and Moore, 2012).
Our ﬁndings are therefore consistent with an additive
effect of the SSBP1 mutation and m.1555A4G, with a
combined effect on mtDNA translation and mtDNA main-
tenance causing a tissue-speciﬁc phenotype. Although there
is both microscopic and molecular evidence of muscle dis-
ease, the patients do not display overt clinical signs of my-
opathy. The clinical features in these individuals were
limited solely to the auditory system.
Taken together, these data suggest rare trans-acting al-
leles are important modiﬁers of the m.1555A4G pheno-
type; this should be taken into consideration for
appropriate genetic counselling of carriers and their
families.
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Figure 3 Continued
levels, Subject P1 = 49.1  16.7, Subject P2 = 41.6  8.1, Subject P3 = 90.6  10.8% of control. Mean  SD of three independent experiments
*P5 0.05, **P5 0.01 one-way ANOVA with post hoc Tukey test. Blood and fibroblast mtDNA levels assayed by qPCR targeting MT-ND1 and B2M
detects no difference between Subjects P1, P2, P3 and controls (n = 3). Data represent mean  SD of three biological replicates (blood data not
shown). (B) Intra-mitochondrial protein translation analysis by incorporation of 35S methionine reveals a clear reduction of mitochondrial protein
synthesis in Subjects P1, P2 and P3 compared to controls. Representative of three independent experiments. The characteristic bands of
mitochondrial encoded proteins are annotated (MT-ND1, MT-ND2, MT-ND3, MT-ND4L, MT-ND5, MT-ND6: NADH dehydrogenase subunit
1,2,3,4L,5,6; MT-CO1, MT-CO2: mitochondrially encoded cytochrome c oxidase, I, II; MT-CYB: mitochondrially encoded cytochrome b; ATP6,
ATP8: mitochondrially encoded ATP synthase 6,8). Loading determined by TOMM20 western blot. [B(i)] Quantification of band intensities from
B. (C) Quantitative PCR analysis reveals no difference in MT-CYB mRNA levels between Subjects P1, P2, P3 and controls. Data represent
mean  SD of three biological replicates. (D) Representative western blot analysis of fibroblast cell lysates from Subjects P1, P2, P3 and controls
reveals reduced steady state levels of MT-CO1 and MT-CO2 without change in nuclear encoded mitochondrial proteins ATP5A (ATP synthase
subunit alpha) and SDHA (succinate dehydrogenase complex flavoprotein subunit A). [D(i)] Quantification of MT-CO1 (solid bars) and MT-CO2
(hashed bars) reveals a trend towards reduced MT-CO1 in Subjects P1 and P2 and significantly reduced MT-CO2 in Subjects P1, P2 and P3
compared to controls. Data represent mean  SD of three independent experiments, **P5 0.01, one-way ANOVA with post hoc Tukey test.
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